Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia

References

• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primer. 2015;1(1):15067.
   PubMedGoogle Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295–307.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15–33.
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(S2):S12–S21.
   PubMedGoogle Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–899.
   PubMed Web of Science ®Google Scholar
• Baldez DP, Biazus TB, Rabelo-da-Ponte FD, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:265–275.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19 Suppl 1:38–52.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Rxulti (brexpiprazole) summary of product characteristics [Internet]. cited 2022 Oct 5]. Available from 2022 Oct 5: https://www.ema.europa.eu/en/documents/product-information/rxulti-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Reagila (cariprazine) summary of product characteristics [Internet]. 2018 cited 2022 Oct 5]. Available from 2022 Oct 5: https://www.ema.europa.eu/en/medicines/human/EPAR/reagila.
   Google Scholar
• Intra-Cellular Therapies, Inc. Caplyta (lumateperone) summary of product characteristics [Internet]. 2022 cited 2022 Oct 13]. Available from 2022 Oct 13: https://www.intracellulartherapies.com/docs/caplyta_pi.pdf.
   Google Scholar
• Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.
   PubMed Web of Science ®Google Scholar
• Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83(1):SU21204IP1.
   Web of Science ®Google Scholar
• Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2022;22(1).
   Google Scholar
• Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci. 2021;22(9):4467.
   PubMed Web of Science ®Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.
   PubMedGoogle Scholar
• Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506.
   PubMed Web of Science ®Google Scholar
• Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. Npj Schizophr. 2021;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT. Trace amine-associated receptor 1 as a target for the development of new antipsychotics: current status of research and future directions. CNS Drugs. 2021;35(11):1153–1161.
   PubMed Web of Science ®Google Scholar
• Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185.
   PubMed Web of Science ®Google Scholar
• Lobo MC, Whitehurst TS, Kaar SJ, et al. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324–361.
   PubMed Web of Science ®Google Scholar
• Dodd S,F, Carvalho A, Puri BK, et al. Trace Amine-Associated Receptor 1 (TAAR1): a new drug target for psychiatry? Neurosci Biobehav Rev. 2021;120:537–541.
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, Non-D 2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.
   PubMed Web of Science ®Google Scholar
• Begni V, Sanson A, Luoni A, et al. Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856. Int J Mol Sci. 2021;22(8):4119.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2021;26(6):2562–2576.
   PubMed Web of Science ®Google Scholar
• Synan C, Bowen C, Heal DJ, et al. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend. 2022;231:109261.
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Wu S, et al. Ulotaront improves metabolic parametres in rodent models of weight gain and hyperglycemia. Poster presented at: The 7th Biennial Schizophrenia International Research Society Conference; Florence Italy; 2022 Apr 6-10.
   Google Scholar
• Sunovion and psychogenics announce that SEP-363856 has received FDA breakthrough therapy designation for the treatment of people with schizophrenia [Internet]. cited 2021 Oct 15]. Available from 2021 Oct 15: https://news.sunovion.com/press-releases/press-releases-details/2019/Sunovion-and-PsychoGenics-Announce-that-SEP-363856-Has-Received-FDA-Breakthrough-Therapy-Designation-for-the-Treatment-of-People-with-Schizophrenia/default.aspx.
   Google Scholar
• Galluppi GR, Polhamus DG, Fisher JM, et al. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. CPT Pharmacomet Syst Pharmacol. 2021;10:1245–1254.
   PubMedGoogle Scholar
• Koblan KS, Campbell UC, Hopkins SC et al. A Phase 1 Open Label Safety and Tolerability Study of SEP-363856, a Novel non-D2 Mechanism of Action Molecule, in Patients with Schizophrenia. Presented at: 55th Meeting in the American College of Neuropsychopharmacology; 2016 Dec 4-8; Hollywood, FL.
   Google Scholar
• Berry MD, Gainetdinov RR, Hoener MC, et al. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161–180.
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Hoener MC, Berry MD. Trace amines and their receptors. Pharmacol Rev. 2018;70(3):549–620.
   PubMed Web of Science ®Google Scholar
• Nair PC, Miners JO, McKinnon RA, et al. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol Psychiatry. 2022;27(1):88–94.
   PubMed Web of Science ®Google Scholar
• Liu J-F, Siemian JN, Seaman R, et al. Role of TAAR1 within the subregions of the mesocorticolimbic dopaminergic system in cocaine-seeking behavior. J Neurosci Off J Soc Neurosci. 2017;37(4):882–892.
   PubMed Web of Science ®Google Scholar
• Espinoza S, Salahpour A, Masri B, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol. 2011;80(3):416–425.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Dedic N, Koblan KS. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans. Transl Psychiatry. 2021;11(1):228.
   PubMed Web of Science ®Google Scholar
• Nazimek J, Perini F, Capitao L, et al. A phase 1 functional neuroimaging study of SEP-363856 in healthy volunteers with high or low schizotypy. Presented at: 55th Meeting in the American College of Neuropsychopharmacol. 2016 Dec 4-8; Hollywood, FL.
   Google Scholar
• Sunovion. NCT01994473: a 2-part randomized single-blind, placebo-controlled, ascending multiple oral dose and open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia [Internet]. 2015 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT01994473.
   Google Scholar
• Sunovion. NCT01940159: a randomized single-blind, placebo-controlled, ascending single oral dose study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia. [Internet]. 2014 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT01940159.
   Google Scholar
• Sunovion. NCT04369391: a randomized, single-dose, crossover study of the effects of SEP-363856 on Electrocardiogram (ECG) intervals in subjects with schizophrenia [Internet]. 2020 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04369391.
   Google Scholar
• Sunovion. NCT04865835: a randomized, single-blind, two-period crossover to investigate the effect of SEP-363856 on the pharmacokinetics of metformin in subjects with schizophrenia. [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04865835.
   Google Scholar
• Sunovion. NCT04038957: an open-label positron emission tomography study to investigate the effect of adjunctive administration of SEP-363856 on brain dopamine synthesis capacity using 18F-DOPA in adult subjects with schizophrenia [Internet]. 2020 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04038957.
   Google Scholar
• Sumitomo Dainippon Pharma Co., Ltd. NCT03370640: a 2-part ascending multiple oral dose, open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia. [Internet]. 2018 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT03370640.
   Google Scholar
• Sumitomo Dainippon Pharma Co., Ltd. NCT04325737: a randomized, double-blind, placebo-controlled, multiple oral dose study assessing the safety and tolerability of SEP-363856 in Japanese subjects with schizophrenia [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04325737.
   Google Scholar
• Sunovion. NCT05463770: an open-label, fixed sequence, multiple dose study of glucose and insulin associated parameters: SEP-363856 vs Prior Antipsychotic (PA) standard of care in subjects with schizophrenia suffering from metabolic dysregulation [Internet]. 2022 cited 2022 Jul 27]. Available from 2022 Jul 27: https://clinicaltrials.gov/ct2/show/NCT05463770.
   Google Scholar
• Sunovion. NCT05402111: a randomized, open-label, single dose, cross-over study of gastric emptying rate: SEP-363856 vs prior antipsychotic standard of care in subjects with schizophrenia [Internet]. 2022 cited 2022 Jul 27]. Available from 2022 Jul 27: https://clinicaltrials.gov/ct2/show/NCT05402111.
   Google Scholar
• Hopkins SC, Ogirala A, Loebel A, et al. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr Bull. 2018;44(3):593–602.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Ogirala A, Loebel A, et al. Understanding antipsychotic drug treatment effects: a novel method to reduce pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) factors. Innov Clin Neurosci. 2017;14(11–12):54–58.
   PubMedGoogle Scholar
• Hopkins SC, Ogirala A, Loebel A, et al. Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM). Psychiatry Res. 2020;294:113569.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Tomioka S, Ogirala A, et al. Assessment of negative symptoms in clinical trials of acute schizophrenia: test of a novel enrichment strategy. Schizophr Bull Open. 2022;3(1):sgac027.
   Google Scholar
• Hopkins SC, Ogirala A, Worden M, et al. Depicting safety profile of TAAR1 agonist ulotaront relative to reactions anticipated for a dopamine D2-based pharmacological class in FAERS. Clin Drug Investig. 2021;41(12):1067–1073.
   PubMed Web of Science ®Google Scholar
• Sunovion. NCT04072354: a randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of SEP-363856 in acutely psychotic subjects with schizophrenia [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04072354.
   Google Scholar
• Sunovion. NCT04092686: a randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of SEP-363856 in acutely psychotic subjects with schizophrenia [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04092686.
   Google Scholar
• Sunovion. NCT04109950: an open-label extension study to assess the safety and tolerability of Sep-363856 in subjects with schizophrenia [Internet]. 2020 cited 2021 Sep 21]. Available from 2021 Sep 21: https://clinicaltrials.gov/ct2/show/NCT04109950.
   Google Scholar
• Sunovion. NCT04115319: a randomized, double-blind, active comparator-controlled study to evaluate the long-term safety and tolerability of SEP-363856 in subjects with schizophrenia [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04115319.
   Google Scholar
• Sumitomo Dainippon Pharma Co., Ltd. NCT04825860: a randomized, double-blind, parallel-group, placebo controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of SEP 363856 in acutely psychotic patients with schizophrenia, followed by an open-label extension phase [Internet]. 2021 cited 2021 Dec 10]. Available from 2021 Dec 10: https://clinicaltrials.gov/ct2/show/NCT04825860.
   Google Scholar
• Sumitomo Pharma Co., Ltd. NCT05359081: a 52-week, open-label study to evaluate the long-term safety and tolerability of SEP-363856 in patients with schizophrenia in Japan [Internet]. 2022 cited 2022 May 11]. Available from 2022 May 11: https://clinicaltrials.gov/ct2/show/NCT05359081.
   Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20.
   PubMedGoogle Scholar
• Tandon R, Lenderking WR, Weiss C, et al. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann Gen Psychiatry. 2020;19(1):42.
   PubMed Web of Science ®Google Scholar
• Bugda Gwilt K, González DP, Olliffe N, et al. Actions of trace amines in the brain-gut-microbiome axis via trace amine-associated receptor-1 (TAAR1). Cell Mol Neurobiol. 2020;40(2):191–201.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(3):261–269.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Stubbs B, et al. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2017;211(6):339–349.
   PubMed Web of Science ®Google Scholar
• Taipale H, Schneider-Thoma J, Pinzón-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatry. 2022;79(3):210–218.
   PubMed Web of Science ®Google Scholar
• Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13:155–172.
   PubMedGoogle Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67:160–161.
   PubMed Web of Science ®Google Scholar
• Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131:58–62.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.
   PubMed Web of Science ®Google Scholar
• Menke A. Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharmacogenomics Pers Med. 2018;11:211–222.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Stahl SM. Precision and personalized assessment, diagnosis and treatment in psychiatry. CNS Spectr. 2021;26:326–332.
   PubMed Web of Science ®Google Scholar